Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

Enhertu is supplied in a single-dose vial containing 100mg of lyophilized powder for reconstitution and further dilution prior to IV infusion. Patients should be selected for treatment with ...

The list price of Datroway is $4,891.07 per vial, AstraZeneca said ... AstraZeneca and Daiichi's first co-developed ADC, Enhertu, was first approved by the FDA in 2019 for a type of breast ...

The list price of Datroway is $4,891.07 per vial, AstraZeneca said ... AstraZeneca and Daiichi’s first co-developed ADC, Enhertu, was first approved by the FDA in 2019 for a type of breast ...

Datroway will cost nearly $4,900 per vial, Reuters reported. The treatment will hit U.S ... In this setting, however, Datroway would compete with the partners’ own Enhertu, which is approved for ...

Enhertu achieved a median progression-free survival of 13.2 months versus 8.1 months for chemotherapy, with a higher objective response rate of 62.6% compared to 34.4%. This summary was ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for an expanded indication of ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application (sBLA) seeking approval for expanded use of Enhertu (trastuzumab ...

Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer after endocrine therapy progression, based on DESTINY-Breast06 trial results. Enhertu showed a 36% reduction in ...